Company news

Meet the team presenting and exhibiting at the 21st Annual International Meeting of ISPOR, the International Society of Pharmacoeconomics and Outcomes Research, taking place 23rd–25th May in Washington DC. Building on the success of previous ISPOR conferences, this year we will be hosting two workshops and presenting… Read More

We are honoured to have been invited to present at the 7th Annual Critical Path Institute Patient-Reported Outcome (PRO) Consortium Workshop to be held in Silver Spring, Maryland on 27th-28th April 2016. Rob Arbuckle, Managing Director of our UK Patient-Centered Outcomes practice, will be presenting two case studies as part… Read More

Increasing numbers of rare diseases are being recognised and more medicines to treat them are being developed. There are several unique challenges for developing evidence packages in rare diseases such as the paucity of information on patient populations, disease progression and appropriate Clinical Outcome Assessments (COAs). As with all clinical… Read More

Oncology is an area that is notoriously hard to achieve patient-reported outcome label claims, but experts at Adelphi Values continue to evaluate ways to work with the FDA guidelines to ensure data are robust and stand up to the scrutiny of regulators. To demonstrate this, and in collaboration with Novartis,… Read More

This week we are attending the 6th Annual World Orphan Drug Congress in Geneva, Switzerland. We are pleased to be presenting a poster entitled ‘Development of patient-centred outcomes in rare diseases’ which will focus on the need for the development of new treatments for rare diseases and indications with orphan… Read More

We are exhibiting and presenting at the 18th Annual European Conference of ISPOR, the International Society for Pharmacoeconomics and Outcomes Research, which takes place from 9th-11th November 2015 in Milan, Italy. Representatives from each of our four practices and both the UK and US offices, will be attending the event. Read More

We are delighted to have recently been invited to present during the prestigious eCOA Forum Scientific Sessions which will be taking place at Oxford University, United Kingdom on 27th-29th October 2015.  Hosted by CRF Health, the conference brings together some of the healthcare industry’s leading professionals and will incorporate educational… Read More

On October 5th 2015, Alan Shields, PhD from Adelphi Values USA will be chairing a session entitled ‘Use and Usefulness of PRO Endpoints in Oncology Trials’ to be held from 12pm to 5pm.  This session is part of a broader DIA (Drug Information Association) conference in Bethesda, Maryland, USA entitled… Read More

In an ever-changing healthcare environment, the need to prove value for money remains a key focus for payers and reimbursement decision makers. Broad-based healthcare reforms, new pricing regulations, increasing tendering processes and emphasis on value-based assessment are all changing the game for pricing and reimbursement, while raising hurdles for market access. Read More

Adelphi Values is pleased to report that on 29 April 2015 the US FDA granted approval of KYBELLA™ indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. Developed by Kythera Biopharmaceuticals®,  KYBELLA™ is the FIRST and ONLY approved non-surgical treatment… Read More

There is growing momentum among researchers, regulatory agencies, policy makers and payers towards a more patient-centric approach to health outcomes research and participation of patients in clinical trials. On 25 June 2015 at 3pm (GMT) PMGroup, in association with Adelphi Values, will host a free webinar showing how a more… Read More

In clinical trials, we put a lot of thought into asking patients how they feel about their disease. But often we neglect to ask them what they think about the trial itself. This feedback can be crucial in improving trial design and execution, and ensuring trials are patient-centric. In order… Read More

Adelphi will be at ISPOR US in May, exhibiting at booths 411/413.  Senior representatives from Adelphi Values will be there alongside colleagues from our sister company Adelphi Real World. The theme for the conference this year is titled ‘Integrating Big Data, Patient Data, and Cost-Effectiveness into Clinical Practice: Promise and… Read More

Once again, Adelphi Values has been invited to participate in the C-Path Patient-Reported Outcome Consortium Workshop which will be taking place in Silver Spring, MD on 29-30th April 2015. Alan Shields, SVP, Endpoint Development & Outcomes, will participate in a discussion panel titled ‘Patient Reported Endpoints and the… Read More

Announcing a newly created global leadership team and growth in our senior management team with three new recruits in recent weeks. Established in 1993, Adelphi Values has been a global leader in patient-centered and healthcare value research for over 20 years. Throughout this time, we have expanded our offering to… Read More

Cheryl Coon, Associate Director from our Endpoint Development & Outcomes Assessment practice will be presenting at the DIA 2014 50th Annual Meeting in San Diego on June 19th. The session titled ‘Moving Beyond the Traditional Psychometric Validation of New Phase 3 Clinical Outcome Assessments’ will be on June 19, 9:00AM… Read More

We are delighted to be speaking at the upcoming eCOA Forum Scientific Sessions on June 24-25 in Oxford, United Kingdom. Hosted by CRF Health, the meeting brings together world leaders in PRO development and Health Outcomes and focuses on current approaches to questionnaire development, design, validation and migration… Read More

We will be exhibiting at the ISPOR 19th annual international meeting at the Palais des Congrès in Montreal May 31 – June 4 2014. Come along to stand 128-129 to meet some of the team and discuss the challenges of developing and commercialising healthcare products and services. Alternatively, we have… Read More

We are delighted to report that on February 18 2014, Chelsea Therapeutics announced that the US Food and Drug Administration (FDA) granted accelerated approval of NortheraTM (Droxidopa) for the treatment of symptomatic neurogenic hypotension (NOH).  Not only is this the first new treatment for NOH in nearly… Read More

Adelphi Values is pleased to announce a senior-level addition to its global Endpoint Development and Outcomes Assessment (EDOA) practice. On September 3rd Cheryl Coon will join Adelphi Values as an Associate Director from RTI Health Solutions, where she was most recently Director of Psychometrics. With over 10 years of experience… Read More